Article Text

Download PDFPDF
Supplement
Advances in targeted therapies XIV
  1. Ferry C Breedveld1,
  2. J R Kalden2,
  3. Josef S Smolen3
  1. 1Rheumatology C4-r, University Hospital Leiden, Leiden, The Netherlands
  2. 2Institute for Clinical Immun. and Rheum., Erlangen, Germany
  3. 3Department of Rheumatology, Medical University of Vienna, Vienna, Austria
  1. Correspondence to Professor Ferry C Breedveld, Rheumatology C4-r, University Hospital Leiden, Leiden 2300 RC, The Netherlands; f.c.breedveld{at}lumc.nl

Statistics from Altmetric.com

The papers brought together in this supplement of the Annals of the Rheumatic Diseases constitute summaries of presentations at the 14th International Symposium on Advances in Targeted Therapies, which was held from 28 March till 1 April 2012. As such, these presentations represent the state-of-the-art on the biology of mechanisms of action and pathophysiology of tumour necrosis factor (TNF), as well as other important mediators of inflammation. Current knowledge on the means and consequences of blocking TNF or other molecules or cellular mechanisms is presented as well.

We are grateful to Drs Crofford, …

View Full Text

Footnotes

  • i The conference was organised under the sole responsibility of the departments of the Universities of Erlangen, Leiden and Vienna in collaboration with an Advisory Board consisting of the above-mentioned colleagues from departments of rheumatology of several US and European Universities. The following companies provided unrestricted educational grants for the organisation of this conference: Abbott, Amgen, Bristol-Myers Squibb, Mitsubishi Tanabe, Pfizer, Roche, Savient Pharmaceuticals, and UCB. The pharmaceutical industry had no part in the decisions regarding the specific programme and, with the exception of few observers; participants were selected and solely invited by the Organising Committee. Several members of the Advisory Board and the members of the Organising Committee have obtained experience in the use of biologic compounds in the course of their participation in clinical studies on these agents (for which the costs were defrayed by industry).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.